Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

Kennedy has promised to "Make America Healthy Again" by tackling obesity with nutrition. Here's how he could rattle the ...

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

The Ipsos survey of 1,078 adults found 24 of people would use weight-loss jabs if they were provided for free by the health service.

More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

Ethics Board Approval Granted for Lexaria Receives Ethics Board Approval for 12-Week Phase 1b DehydraTECH GLP-1 Study in ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

These claim to work in myriad different ways but “they have not been approved formally for weight loss,” says Prof Miras ... while Wegovy is prescribed by the NHS for weight management, Rybelsus is ...

The best online providers offer strong support services to help you succeed in your GLP-1 weight loss journey.

Ozempic and related GLP-1 drugs have taken Europe and North America by storm and have quickly become the darling of the ...